Why Bausch Health (BHC) Shares Are Trading Higher Today - Bausch Health Companies (NYSE:BHC)

Bausch Health Companies Inc BHC reported Q4 revenues of $2.2 billion, flat Y/Y, up 4% organic basis, above the consensus estimate of $2.14 billion.
"2022 was a transformative year for Bausch Health, as we executed our strategic priorities," said Thomas Appio, CEO of Bausch Health. "Since completing the initial public offering of Bausch + Lomb last May, we have made significant progress in de-levering our balance sheet, reducing our principal debt net of unrestricted cash by $3.2 billion.
The company reported an EPS loss of ($1.13) compared with an income of $0.19 last year.
Adjusted EBITDA fell to $823 million from $909 million.
Related: Bausch Health Investors Request Blocking Eye-Care Business Spinoff, Alleging Protection From Lawsuits.
Guidance: Bausch Health is not providing consolidated full-year guidance, as Bausch + Lomb has not provided full-year guidance.
Bausch Health (excl. B+L) expects FY23 sales of $4.45 - $4.6 billion and Adjusted EBITDA of $2.3 - $2.4 billion.
Price Action: BHC shares are up 11.1% at $9.60 on the last check Thursday.

Momentum16.26

Growth51.34

Quality-

Value43.05

Short

Medium

Long

Why Bausch Health Shares Are Trading Higher Today